Monoclonal antibodies for tumor treatment
US8747847B2 · kind B2 · utility
26Cited by
4References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2009 |
| Grant date | Jun 10, 2014 |
| Priority date | — |
| Expiry date | Aug 26, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/3061
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.